Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5529-5534

  Smith, Jordan R ^a   Barber, Katie E ^a   Hallesy, Jessica ^a   Raut, Animesh ^a   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; COMPARTMENT MODEL; CONTROLLED STUDY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84940938031     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00773-15     Document Type: Article

References (18)

1. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2011. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn Microbiol Infect Dis 71:93-97. http://dx.doi.org/10 .1016/j.diagmicrobio.2011.05.012.
2. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). Diagn Microbiol Infect Dis 72:113-117. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.023.
3. Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ. 2012. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:5528-5533. http://dx.doi.org /10.1128/AAC.00922-12.
4. Steed ME, Vidaillac C, Rybak MJ. 2012. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:955-959. http://dx.doi.org/10 .1128/AAC.05849-11.
5. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. 2015. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother 59:1811-1814. http://dx.doi.org /10.1128/AAC.04616-14.
6. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE, Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127-1134. http://dx.doi.org/10.1128/AAC.49.3 .1127-1134.2005.
7. Lunde CS, Rexer CH, Hartouni SR, Axt S, Benton BM. 2010. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother 54:2198-2200. http://dx.doi.org/10.1128/AAC.01609-09.
8. Jones RN, Streit JM, Fritsche TR. 2004. Validation of commercial dryform broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 23:197-199. http://dx.doi.org/10.1016/j.ijantimicag.2003.07 .008.
9. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399-403. http://dx.doi.org/10.1093/jac /47.4.399.
10. th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245-3249. http://dx.doi.org/10.1128 /AAC.00247-06.
12. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45:1843-1846. http://dx.doi.org/10 .1128/AAC.45.6.1843-1846.2001.
13. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49:195-201. http://dx.doi.org/10.1128/AAC.49.1.195-201.2005.
14. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. 2013. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect." Antimicrob Agents Chemother 57:2664-2668. http://dx.doi.org/10.1128/AAC.02308-12.
15. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 56:3999-4004. http://dx.doi.org/10.1128 /AAC.00011-12.
16. Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. 2014. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 81:275-279.
17. Leonard SN, Vidaillac C, Rybak MJ. 2009. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 53:2928-2933. http://dx.doi.org/10.1128/AAC.01544-08.
18. Theravance. 2014. Telavancin package insert. Theravance, South San Francisco, CA. http://www.vibativ.com/docs/VIBATIV-PI-Final.pdf.